Literature DB >> 18815873

Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity.

Emilio L Streck1, Giselli Scaini, Gislaine T Rezin, Jeverson Moreira, Celine M Fochesato, Pedro R T Romão.   

Abstract

Nevirapine (NVP) and efavirenz (EFV) are antiretroviral drugs belonging to potent class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) widely used for the treatment human immunodeficiency virus (HIV) infection. It has been demonstrated that NVP and EFV are able to cross the blood-brain barrier and arrive at the central nervous system (CNS), causing important adverse effects related to their presence within this tissue. Considering that the exact mechanisms responsible for CNS toxicity associated with NVP and EFV remain unknown and that creatine kinase (CK) plays an important role in cell energy homeostasis, in the present work we evaluated CK activity in brain of mice after chronic administration of these drugs. Our results demonstrated that NVP and EFV significantly inhibited CK activity in cerebellum, hippocampus, striatum and cortex of mice. Although it is difficult to extrapolate our findings to the human condition, the inhibition of brain CK activity by NVP and EFV may be associated with neurological adverse symptoms of these drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18815873     DOI: 10.1007/s11011-008-9109-2

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  44 in total

1.  Octamers of mitochondrial creatine kinase isoenzymes differ in stability and membrane binding.

Authors:  U Schlattner; T Wallimann
Journal:  J Biol Chem       Date:  2000-06-09       Impact factor: 5.157

2.  A method for the estimation of serum creatine kinase and its use in comparing creatine kinase and aldolase activity in normal and pathological sera.

Authors:  B P HUGHES
Journal:  Clin Chim Acta       Date:  1962-09       Impact factor: 3.786

3.  Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis.

Authors:  Markus Bickel; Christoph Stephan; Carsten Rottmann; Amina Carlebach; Anette Haberl; Michael Kurowski; Schlomo Staszewski
Journal:  Scand J Infect Dis       Date:  2005

Review 4.  The creatine-creatine phosphate energy shuttle.

Authors:  S P Bessman; C L Carpenter
Journal:  Annu Rev Biochem       Date:  1985       Impact factor: 23.643

Review 5.  Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia?

Authors:  J P Blass
Journal:  J Neurosci Res       Date:  2001-12-01       Impact factor: 4.164

6.  Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Authors:  C Marzolini; A Telenti; L A Decosterd; G Greub; J Biollaz; T Buclin
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

7.  Structural and behavioural consequences of double deficiency for creatine kinases BCK and UbCKmit.

Authors:  Femke Streijger; Frank Oerlemans; Bart A Ellenbroek; Carolina R Jost; Bé Wieringa; Catharina E E M Van der Zee
Journal:  Behav Brain Res       Date:  2005-02-28       Impact factor: 3.332

8.  Modulation of creatine kinase activity by ruthenium complexes.

Authors:  Francine Zanette; Eduardo G Victor; Giselli Scaini; Priscila B Di-Pietro; Danon C Cardoso; Maykon P Cristiano; Felipe Dal-Pizzol; Marcos M S Paula; Emilio L Streck
Journal:  J Inorg Biochem       Date:  2006-10-11       Impact factor: 4.155

9.  Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.

Authors:  Félix Gutiérrez; Andrés Navarro; Sergio Padilla; Rosa Antón; Mar Masiá; Joaquín Borrás; Alberto Martín-Hidalgo
Journal:  Clin Infect Dis       Date:  2005-10-19       Impact factor: 9.079

Review 10.  Neuropsychiatric side effects of efavirenz therapy.

Authors:  Gabriele Arendt; Dominique de Nocker; Hans-Juergen von Giesen; Thorsten Nolting
Journal:  Expert Opin Drug Saf       Date:  2007-03       Impact factor: 4.250

View more
  17 in total

1.  HIV Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz Reduces Neural Stem Cell Proliferation in Vitro and in Vivo.

Authors:  Jingji Jin; Bethany Grimmig; James Izzo; Lecia A M Brown; Charles Hudson; Adam J Smith; Jun Tan; Paula C Bickford; Brian Giunta
Journal:  Cell Transplant       Date:  2016-11       Impact factor: 4.064

2.  Interaction Effects between HIV and Aging on Selective Neurocognitive Impairment.

Authors:  Yingying Ding; Haijiang Lin; Weiwei Shen; Qionghai Wu; Meiyang Gao; Na He
Journal:  J Neuroimmune Pharmacol       Date:  2017-05-03       Impact factor: 4.147

3.  HIV-associated neurodegeneration and neuroimmunity: multivoxel MR spectroscopy study in drug-naïve and treated patients.

Authors:  Jasmina Boban; Dusko Kozic; Vesna Turkulov; Jelena Ostojic; Robert Semnic; Dajana Lendak; Snezana Brkic
Journal:  Eur Radiol       Date:  2017-03-14       Impact factor: 5.315

4.  8-Hydroxy-efavirenz, the primary metabolite of the antiretroviral drug Efavirenz, stimulates the glycolytic flux in cultured rat astrocytes.

Authors:  Maria Brandmann; Uwe Nehls; Ralf Dringen
Journal:  Neurochem Res       Date:  2013-10-04       Impact factor: 3.996

5.  Anti-HIV drugs nevirapine and efavirenz affect anxiety-related behavior and cognitive performance in mice.

Authors:  Pedro R T Romão; Joelson C Lemos; Jeverson Moreira; Gisele de Chaves; Morgana Moretti; Adalberto A Castro; Vanessa M Andrade; Carina R Boeck; João Quevedo; Elaine C Gavioli
Journal:  Neurotox Res       Date:  2009-12-10       Impact factor: 3.911

6.  Neuronal-Glia Markers by Magnetic Resonance Spectroscopy in HIV Before and After Combination Antiretroviral Therapy.

Authors:  Napapon Sailasuta; Jintanat Ananworanich; Sukalaya Lerdlum; Pasiri Sithinamsuwan; James L K Fletcher; Somporn Tipsuk; Mantana Pothisri; Tanate Jadwattanakul; Supunnee Jirajariyavej; Thep Chalermchai; Stephanie Catella; Edgar Busovaca; Akash Desai; Robert Paul; Victor Valcour
Journal:  J Acquir Immune Defic Syndr       Date:  2016-01-01       Impact factor: 3.731

Review 7.  Neurological and psychiatric adverse effects of antiretroviral drugs.

Authors:  Michael S Abers; Wayne X Shandera; Joseph S Kass
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

Review 8.  Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics.

Authors:  Ankit Shah; Mohitkumar R Gangwani; Nitish S Chaudhari; Alexy Glazyrin; Hari K Bhat; Anil Kumar
Journal:  Neurotox Res       Date:  2016-06-30       Impact factor: 3.911

9.  HIV nonnucleoside reverse transcriptase inhibitors and trimethoprim-sulfamethoxazole inhibit plasmodium liver stages.

Authors:  Charlotte V Hobbs; Tatiana Voza; Patricia De La Vega; Jillian Vanvliet; Solomon Conteh; Scott R Penzak; Michael P Fay; Nicole Anders; Tiina Ilmet; Yonghua Li; William Borkowsky; Urszula Krzych; Patrick E Duffy; Photini Sinnis
Journal:  J Infect Dis       Date:  2012-12-01       Impact factor: 5.226

10.  Brain creatine kinase activity is inhibited after hepatic failure induced by carbon tetrachloride or acetaminophen.

Authors:  Gustavo S Pacheco; Jordana P Panatto; Diego A Fagundes; Giselli Scaini; Cintia Bassani; Isabela C Jeremias; Gislaine T Rezin; Larissa Constantino; Felipe Dal-Pizzol; Emilio L Streck
Journal:  Metab Brain Dis       Date:  2009-08-18       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.